Literature DB >> 23521603

Increased risk of chemotherapy-associated venous thromboembolism in elderly patients with cancer.

Matteo Vergati1, David Della-Morte, Patrizia Ferroni, Vittore Cereda, Livia Tosetto, Francesca La Farina, Fiorella Guadagni, Mario Roselli.   

Abstract

Data on the relationship between aging, chemotherapy, and risk for venous thromboembolism (VTE) are controversial. We sought to evaluate the risk of chemotherapy-associated VTE in young to middle-aged (YMA) and elderly cancer patients and to analyze the VTE-free survival time in both groups. Patients with histologically confirmed diagnosis of solid malignancy receiving any type of systemic chemotherapy, no clinical diagnosis of VTE before chemotherapy initiation, and Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤2 were enrolled in this study. Of the 486 consecutive patients included in the study, 380 (78%) were classified as YMA (≤70 years of age) and 106 (22%) as elderly (>70 years of age). At a median follow-up of 1 year, the incidence of VTE events was almost two-fold greater in elderly than in YMA (11% vs. 6%). Age (≤70 years vs. >70 years (hazard ratio [HR], 2.42; 95% confidence interval [CI] 1.15-5.06; p=0.020), ECOG-PS (HR, 6.54; 95% CI 3.10-13.8; p<0.0001), and platinum-based chemotherapy (HR, 2.46; 95% CI 1.06-5.69; p=0.035) were independent risk factors for VTE. In the elderly subset, a trend toward an increased risk of VTE in patients receiving a platinum-based chemotherapy when compared with a non-platinum-containing regimen was observed (15% vs. 9.1%). The Kaplan-Meier analysis showed that elderly patients had a significantly shorter VTE-free survival time compared with younger cancer patients (log-rank test=2.0; p=0.045). Our study reports an increase incidence of VTE in elderly cancer patients treated with chemotherapy compared with the younger group, suggesting that aging is one of the most important risk factors for VTE. On the basis of the results of this study, we believe that a validated predictive model including age, ECOG-PS, and type of chemotherapy (platinum- vs. non-platinum containing regimen) would enable clinicians to target thromboprophylaxis to those patients considered to be at greatest risk.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23521603     DOI: 10.1089/rej.2013.1409

Source DB:  PubMed          Journal:  Rejuvenation Res        ISSN: 1549-1684            Impact factor:   4.663


  7 in total

Review 1.  Venous Thromboembolism in Cancer Patients on Simultaneous and Palliative Care.

Authors:  Silvia Riondino; Patrizia Ferroni; Girolamo Del Monte; Vincenzo Formica; Fiorella Guadagni; Mario Roselli
Journal:  Cancers (Basel)       Date:  2020-05-06       Impact factor: 6.639

Review 2.  Cancer-Associated Thrombosis: An Overview of Mechanisms, Risk Factors, and Treatment.

Authors:  Norbaini Binti Abdol Razak; Gabrielle Jones; Mayank Bhandari; Michael C Berndt; Pat Metharom
Journal:  Cancers (Basel)       Date:  2018-10-11       Impact factor: 6.639

3.  SILAC Analysis Reveals Increased Secretion of Hemostasis-Related Factors by Senescent Cells.

Authors:  Christopher D Wiley; Su Liu; Chandani Limbad; Anna M Zawadzka; Jennifer Beck; Marco Demaria; Robert Artwood; Fatouma Alimirah; Jose-Alberto Lopez-Dominguez; Chisaka Kuehnemann; Steven R Danielson; Natan Basisty; Herbert G Kasler; Tal Ronnen Oron; Pierre-Yves Desprez; Sean D Mooney; Bradford W Gibson; Birgit Schilling; Judith Campisi; Pankaj Kapahi
Journal:  Cell Rep       Date:  2019-09-24       Impact factor: 9.423

4.  Validation of a Machine Learning Approach for Venous Thromboembolism Risk Prediction in Oncology.

Authors:  Patrizia Ferroni; Fabio M Zanzotto; Noemi Scarpato; Silvia Riondino; Fiorella Guadagni; Mario Roselli
Journal:  Dis Markers       Date:  2017-09-17       Impact factor: 3.434

5.  Risk Prediction and New Prophylaxis Strategies for Thromboembolism in Cancer.

Authors:  Patrizia Ferroni; Fiorella Guadagni; Mario Roselli
Journal:  Cancers (Basel)       Date:  2021-03-29       Impact factor: 6.639

6.  Prognostic Factors for Venous Thromboembolism in Patients with Solid Tumours on Systemic Therapy: A Systematic Review.

Authors:  Sandra Lee; Anika Shenoy; Daniel Shi; Mootaz Husien; Pablo E Serrano; Sameer Parpia
Journal:  TH Open       Date:  2021-09-30

7.  Association of Venous Thromboembolism and Early Mortality in Patients with Newly Diagnosed Metastatic Non-Small Cell Lung Cancer.

Authors:  Yanping Su; Meirong Huo; Lin Hua; Yuan Zhang; Jiawen Yi; Shu Zhang; Jie Li; Yuhui Zhang
Journal:  Cancer Manag Res       Date:  2021-05-18       Impact factor: 3.989

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.